Get the Stockscreener App
13.92
3.73%
-0.54
After Hours:
13.92
Uniqure N V stock is traded at $13.92, with a volume of 1.37M.
It is down -3.73% in the last 24 hours and down -0.14% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$14.46
Open:
$14.41
24h Volume:
1.37M
Relative Volume:
0.91
Market Cap:
$762.48M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-2.1481
EPS:
-6.48
Net Cash Flow:
$-153.08M
1W Performance:
-8.48%
1M Performance:
-0.14%
6M Performance:
-11.56%
1Y Performance:
+81.72%
1-Day Range:
$13.78
$14.60
1-Week Range:
$12.33
$16.29
52-Week Range:
$4.45
$19.18
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
13.92 | 793.38M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure’s AMT-130 Gene Therapy for Huntington’s Disease on Track for Q1 2026 BLA Submission After FDA Alignment - Insider Monkey
How strong is uniQure N.V. company’s balance sheetPost Market Opportunities With High Returns - jammulinksnews.com
Should I hold or sell uniQure N.V. stock in 2025Post Market Picks With Low Risk - jammulinksnews.com
Huntington’s Disease Market to Expand Significantly by 2034, States DelveInsight Report | Prilenia Therapeutics, Neurocrine Biosciences, Som Biotech, Annexon Biosciences, Vaccinex, Sage Therapeutics - Barchart.com
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Yahoo Finance
uniQure N.V. (NASDAQ:QURE) Q2 2025 Earnings Call Transcript - Insider Monkey
uniQure N.V. Earnings Call: Progress Amid Challenges - TipRanks
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Benzinga
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $35 to $35 - 富途牛牛
UniQure outlines planned BLA submission for AMT-130 in Q1 2026 amid regulatory alignment and pipeline momentum - MSN
UniQure shares rise 9.65% premarket after FDA alignment on AMT-130 statistical analysis plan and CMC requirements. - AInvest
uniQure NV (QURE) Q2 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... By GuruFocus - Investing.com Canada
uniQure Reports Q2 2025 Progress and Financials - TipRanks
UniQure: Q2 Earnings Snapshot - Stamford Advocate
Chardan Capital maintains Buy rating for uniQure with $35 PT. - AInvest
uniQure shares tumble as Q2 revenue misses expectations - Investing.com
uniQure Announces $200 Million Sales Agreement - TipRanks
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Uniqure NV earnings beat by $0.20, revenue fell short of estimates - Investing.com Nigeria
uniQure N.V. SEC 10-Q Report - TradingView
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress - TradingView
Huntington's Disease Breakthrough: uniQure's Gene Therapy Gets FDA Fast Track as Patient Data Shows Promise - Stock Titan
What makes uniQure N.V. stock price move sharplyAI Based High Gain Watchlist Scanner Shared - metal.it
uniQure N.V. Crosses 200 Day MA — Signal or NoiseHigh Return Stock Focus With Safety Emphasized - metal.it
What are the technical indicators suggesting about uniQure N.V.Free Stock Trend Scanner For 2025 - jammulinksnews.com
Trend Dashboard Flags uniQure N.V. As Potential Swing TradeWatchlist for Smart Swing Trading Updated - metal.it
What is the risk reward ratio of investing in uniQure N.V. stockUnlock powerful trading tools for investors - jammulinksnews.com
How does uniQure N.V. generate profit in a changing economyInvest confidently with real-time data - jammulinksnews.com
Is uniQure N.V. stock overvalued or undervaluedUnprecedented market success - jammulinksnews.com
How many analysts rate uniQure N.V. as a “Buy”Invest in stocks with long-term growth potential - jammulinksnews.com
Is uniQure N.V. a growth stock or a value stockMarket-beating returns - jammulinksnews.com
What are uniQure N.V. company’s key revenue driversAchieve remarkable returns with smart investing - jammulinksnews.com
uniQure N.V. Stock Analysis and ForecastDynamic profit expansion - PrintWeekIndia
What analysts say about uniQure N.V. stockFree Consultation - PrintWeekIndia
Earnings Preview: UniQure NV to Report Financial Results Pre-market on July 29 - 富途牛牛
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):